Advances in the Pathogenesis and Treatment of Heart Failure and Cardiomyopathy
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 59
Special Issue Editors
Interests: heart failure; photobiomodulation; stem cells
Interests: heart failure
Interests: heart failure; photobiomodulation
Special Issue Information
Dear Colleagues,
Heart failure (HF) is one of the major challenges in cardiovascular disease, characterized by high morbidity and mortality, with a significant impact on public health expenditure. Current guidelines recommend different classes of drugs, invasive procedures, implantable devices, and lifestyle changes to prevent the progression of HF. Despite advances in recent decades, effective therapeutic interventions remain limited. As a result, progressive cardiac dysfunction, reduced functional capacity, and increased mortality remain commonplace. New, evidence-based therapies are therefore essential. These new approaches will pave the way for promising agents to alter the natural history of HF in the future.
This Special Issue aims to contribute to the knowledge of the pathophysiology of HF and cardiomyopathy. We invite authors to submit experimental/laboratory studies investigating new therapies that may prevent or slow the progression of HF, including innovative pharmacologic and gene and cell therapies.
Prof. Dr. Andrey Jorge Serra
Dr. Ednei Luiz Antonio
Dr. Gianna Móes de Albuquerque-Pontes
Dr. Luis Felipe Neves dos Santos
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cardiomyopathy
- cardiac remodeling
- heart disease
- heart failure
- mechanisms
- new therapies
- targeted therapies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
